DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; and collaboration with the University of Texas MD Anderson Cancer Center. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.
http://www.priceseries.com/trade/DMPI-DelMar-Pharmaceuticals-Inc-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2017122820180117.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments